Scarica l'app Stockscreener
15.74
7.29%
1.07
Dopo l'orario di chiusura:
15.74
Inhibrx Biosciences Inc Borsa (INBX) Ultime notizie
Inhibrx Biosciences Concludes 2025 Annual Stockholders Meeting - TipRanks
Inhibrx Slashes Q1 Losses by 45%, Reveals Multiple Clinical Trial Readouts Coming in 2025 - Stock Titan
Oropharyngeal Cancer Treatment Market Size in 7MM is expected - openPR.com
Larynx Cancer Treatment Market Size in 7MM is expected to grow at a decent CAGR by 2032, estimates DelveInsight - openPR.com
Oropharyngeal Cancer Treatment Market Size in 7MM is expected to grow at a decent CAGR by 2032, estimates DelveInsight - Barchart.com
When the Price of (INBX) Talks, People Listen - news.stocktradersdaily.com
(INBX) On The My Stocks Page - news.stocktradersdaily.com
Inhibrx announces leadership changes as co-founder departs - The Pharma Letter
Inhibrx Biosciences reshuffles leadership, appoints new CSO and President By Investing.com - Investing.com South Africa
Inhibrx Biosciences reshuffles leadership, appoints new CSO and President - Investing.com India
Inhibrx Biosciences Announces Departure Of CSO And Appointments Of New CSO And President - TradingView
Inhibrx Biosciences Announces Departure of CSO and Appointments of New CSO and President - PR Newswire
How the (INBX) price action is used to our Advantage - news.stocktradersdaily.com
JMP maintains Market Perform on Inhibrx stock post-earnings - Investing.com India
Inhibrx Biosciences, Inc. SEC 10-K Report - TradingView
Inhibrx Reports Fourth Quarter and Fiscal Year 2024 Financial Results - Yahoo
Long Term Trading Analysis for (INBX) - Stock Traders Daily
Stocks Rebound as US Government Shutdown Seems Averted - The Globe and Mail
When (INBX) Moves Investors should Listen - Stock Traders Daily
Simpson Thacher Adds Partner From Wilson Sonsini - Law360
A closer look at Inhibrx Biosciences Inc (INBX)’s stock price trends - US Post News
BlackRock, Inc. Increases Stake in Inhibrx Biosciences Inc. - GuruFocus.com
(INBX) Trading Signals - Stock Traders Daily
Inhibrx reports promising ozekibart trial results - MSN
Inhibrx's SWOT analysis: oncology biotech stock faces pivotal year ahead - MSN
Inhibrx’s early colorectal cancer data clouded by patient death - Endpoints News
Inhibrx Biosciences Announces Preliminary Data from the Phase 1 - GuruFocus.com
Inhibrx Biosciences Announces Preliminary Data from the Phase 1 Trial of ozekibart (INBRX-109) for the Treatment of Colorectal Cancer – Company Announcement - Financial Times
Inhibrx Biosciences Announces Preliminary Data from the Phase 1 Trial of ozekibart (INBRX-109) for the Treatment of Colorectal Cancer - PR Newswire
How to Take Advantage of moves in (INBX) - Stock Traders Daily
Inhibrx Biosciences enters $150M loan facility - MSN
Regeneron, Illumina invest in Truveta; Inhibrx Bio’s $150M loan - Endpoints News
Inhibrx Biosciences, Inc. Announces Loan Agreement with Oxford Finance LLC - Marketscreener.com
Inhibrx Biosciences Announces Loan Agreement with Oxford Finance - StreetInsider.com
(INBX) Pivots Trading Plans and Risk Controls - Stock Traders Daily
How To Trade (INBX) - Stock Traders Daily
Inhibrx's SWOT analysis: biotech stock faces pivotal year amid clinical trials - Investing.com Canada
2024’s Busiest Dealmakers: Novartis Laps The Field, While Lilly, Sanofi Keep Busy - insights.citeline.com
Trend Tracker for (INBX) - Stock Traders Daily
institutional investors of Inhibrx Biosciences, Inc. (NASDAQ:INBX) must be disappointed after last week's 15% drop - Simply Wall St
Inhibrx Biosciences Reports Third Quarter 2024 Financial Results - PR Newswire
Wilson Sonsini Knocks Out Claims Against Inhibrx Biosciences in Trade Secrets Verdict - Law.com
Inhibrx Biosciences: Reincorporated And Trying To Find A Niche With Unique Platform - Seeking Alpha
Inhibrx Prevails in Trade Secret Case, Reaffirming Its Commitment to Integrity and Innovation - mx.advfn.com
James Sabry on industry-shaping changes in innovation and deal-making - biocentury.com
Inhibrx CEO buys shares worth over $629k By Investing.com - Investing.com UK
Inhibrx: The Biotech Spinoff Poised For Big Gains - Forbes
Inhibrx CEO Mark Lappe buys $596,762 worth of company stock - Investing.com
Hedge Fund and Insider Trading News: Boaz Weinstein, Bill Ackman, Third Point, AQR Capital Management, Inhibrx Biosciences Inc (INBX), Comstock Resources Inc (CRK), and More - Insider Monkey
Inhibrx Biosciences Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights - Finansavisen
Inhibrx stock rated 'Market Perform' by JMP after Sanofi acquisition - Investing.com
Press Release: Sanofi completes acquisition of Inhibrx, Inc. - GlobeNewswire
Inhibrx Inc. Stockholders Approve Sale of INBRX-101 to Sanofi - PR Newswire
Inhibrx, Inc. Announces Updated When-Issued Trading Date for Anticipated Spin-Off - PR Newswire
Inhibrx, Inc. Announces Record Date and Expected Distribution Time for Anticipated Spin-Off and the Expected Merger Effective Time for Anticipated Merger - PR Newswire
Big Pharma Targets Smaller Companies With Megadeals Out of Favor - Bloomberg
Sanofi to Acquire Inhibrx Assets for up to $2.2B - Contract Pharma
Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B - PR Newswire
Inhibrx Granted Fast Track Designation for INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency - PR Newswire
1.45%
0.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):